ERBB2 and cancer: Conversely, the OR for cardiovascular death was lowest in TNBC and highest in HER2+/HR+ cancer (OR: 1.32; 95% CI: 1.09–1.60, p < 0.001), followed by HER2+/HR− cancer (OR: 1.27, 95% CI: 1.01–1.61, p < 0.05), indicating the significant association of these two subtypes with cardiovascular fatalities (Table 3).